Gene editing of PDGFRA with CRISPR/Cas9 in aggressive thyroid cancer cells blunted PDGFRA expression, reduced cell invasion and reversed EMT genes expression (reduced VIM, SLUG, and N-Cadherin and induced E-cadherin). This evidence concerns the gene PDGFRA and thyroid cancer.